Hyderabad based Biological E Limited has revealed that it has completed the Phase II and III trials of its inactivated Japanese Encephalitis (JE) vaccine on healthy kids aged between 1 to 3 years of age.
The trials were conducted in eight different sites across the country and the company revealed that it will be submitted the results of the study to the Indian regulatory authority for licensure.
Commenting on the results of these trials, Dr. Vijay Kumar Datla, Chairman and Managing Director of Biological E. Limited said, "We are excited about the successful completion of our phase-II/III clinical study which enables us to offer this novel and safe vaccine to combat Japanese Encephalitis not only in India but also across Asia."
JE is one of the most common viral encephalitis that occurs in this part of the world. It is estimated that there are around 50,000 cases in Asia on an annual basis with resulting mortality rates ranging from 0.3% to 60%.